Advanced search
Publication Cover
Ocular Immunology and Inflammation Volume 28, 2020 - Issue 3
Submit an article Journal homepage
279
Views
11
CrossRef citations to date
0
Altmetric
Letter to the Editor

Development of Acute Vogt–Koyanagi–Harada-like Syndrome during the Treatment Course with Vemurafenib for Metastatic Melanoma

Atitaya ApivatthakakulDepartment of Ophthalmology, Faculty of Medicine, Chiang Mai University, Chiang Mai, ThailandView further author information
, MD,
Paradee KunavisarutDepartment of Ophthalmology, Faculty of Medicine, Chiang Mai University, Chiang Mai, ThailandORCID Iconhttps://orcid.org/0000-0003-4997-6285View further author information
, MDORCID Icon,
Aniki RothovaDepartment of Ophthalmology, Erasmus Medical Centre, Rotterdam, The NetherlandsView further author information
, MD, PhD &
Kessara PathanapitoonDepartment of Ophthalmology, Faculty of Medicine, Chiang Mai University, Chiang Mai, ThailandCorrespondence[email protected] [email protected]
ORCID Iconhttps://orcid.org/0000-0003-4447-1704View further author information
, MD, PhDORCID Icon
Pages 505-508 | Received 02 Feb 2019, Accepted 18 Mar 2019, Published online: 04 Jun 2019

Citations (11)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Shuohan Huang, Zihan Guo, Mengmeng Wang, Youjun She, Xuan Ye, Qing Zhai, Jiyong Liu & Qiong Du. (2023) Ocular adverse events associated with BRAF and MEK inhibitor combination therapy: a pharmacovigilance disproportionality analysis of the FDA adverse event reporting system. Expert Opinion on Drug Safety 22:2, pages 175-181.
Read now
Andrew M Philip, Stephen D Anesi, C Stephen Foster & Peter Chang. (2022) Ocular Inflammatory Complications of Treatment for Metastatic Melanoma. Ocular Immunology and Inflammation 0:0, pages 1-5.
Read now

Articles from other publishers (9)

Aline MadoePieter-Paul Schauwvlieghe & Julie Jacob. (2023) VOGT–KOYANAGI–HARADA DISEASE-LIKE UVEITIS IN A PATIENT WITH ADVANCED MELANOMA TREATED BY SEQUENTIAL ADMINISTRATION OF NIVOLUMAB AND DABRAFENIB/TRAMETINIB THERAPY. RETINAL Cases & Brief Reports 17:5, pages 611-615.
Crossref
Masaki Takeuchi, Akira Meguro, Jutaro Nakamura, Rei Chikagawa, Raiga Osada, Etsuko Shibuya, Yukiko Hasumi, Norihiro Yamada, Mami Ishihara & Nobuhisa Mizuki. (2023) HLA-DRB1*04:05 is involved in the development of Vogt–Koyanagi–Harada disease-like immune-related adverse events in patients receiving immune checkpoint inhibitors. Scientific Reports 13:1.
Crossref
Clara M. Castillejo Becerra, Wendy M. Smith & Lauren A. Dalvin. (2022) Ophthalmic adverse effects of BRAF inhibitors. European Journal of Ophthalmology 33:2, pages 1224-1231.
Crossref
Dongchen Li, Li Yang, Feng Bai, Shun Zeng & Xiaoli Liu. (2022) Clinical Manifestations, Diagnosis, Treatment and Prognosis of Uveitis Induced by Anticancer Drugs: A Review of Literature. Brain Sciences 12:9, pages 1168.
Crossref
Aditya Rali, Ye Huang & Steven Yeh. (2022) Cancer Immunotherapy and Uveitis: Balancing Anti-Tumor Immunity and Ocular Autoimmunity. International Ophthalmology Clinics 62:3, pages 49-63.
Crossref
Z. Böcskei, E. Viinikka, L. Dormegny, K. Bigaut & C. Speeg. (2022) Ophtalmies paranéoplasiques. Journal Français d'Ophtalmologie 45:1, pages 119-136.
Crossref
Maram E.A. Abdalla Elsayed & Igor Kozak. (2021) Pharmacologically induced uveitis. Survey of Ophthalmology 66:5, pages 781-801.
Crossref
Blake H. Fortes, Prashant D. Tailor & Lauren A. Dalvin. (2021) Ocular Toxicity of Targeted Anticancer Agents. Drugs 81:7, pages 771-823.
Crossref
. (2020) Vemurafenib. Reactions Weekly 1803:1, pages 230-230.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.